Get the Stockscreener App
0.571
0.62%
0.0035
Femasys Inc stock is traded at $0.571, with a volume of 1.04M.
It is up +0.62% in the last 24 hours and down -34.77% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$0.5675
Open:
$0.6
24h Volume:
1.04M
Relative Volume:
3.35
Market Cap:
$18.60M
Revenue:
$950.10K
Net Income/Loss:
$-16.69M
P/E Ratio:
-0.688
EPS:
-0.83
Net Cash Flow:
$-15.16M
1W Performance:
-19.59%
1M Performance:
-34.77%
6M Performance:
-65.18%
1Y Performance:
-43.47%
1-Day Range:
$0.5452
$0.60
1-Week Range:
$0.5452
$0.7254
52-Week Range:
$0.5452
$1.80
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.571 | 22.81M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
476.16 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
199.66 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
82.02 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
293.73 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
247.85 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
Femasys Inc Stock (FEMY) Latest News
Femasys Gains UK Approval for FemBloc Birth Control - TipRanks
Femasys receives UK regulatory approval for non-surgical birth control - Investing.com
Femasys secures U.K. Regulatory Approval of FemBloc permanent birth control - TipRanks
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control - GlobeNewswire
First Non-Surgical Permanent Birth Control: Femasys FemBloc Gets UK Green Light After CE Mark - Stock Titan
Femasys Gains European Approval for FemBloc System - MSN
Femasys Secures First European Order for Non-Surgical Contraceptive FemBloc - Femtech Insider
Is Femasys Inc. Forming a Bottom PatternGold Moves & Detailed Earnings Play Strategies - kangso.co.kr
Why Femasys Inc. stock attracts strong analyst attentionWeekly Market Outlook & AI Powered Market Entry Strategies - thegnnews.com
Is Femasys Inc. in a bullish channel2025 Market Outlook & Expert Approved Trade Ideas - thegnnews.com
Femasys Receives Bullish Rating from Maxim Group Analyst Due to Strategic Initiatives and Product Innovations - AInvest
Optimistic Buy Rating for Femasys Driven by Strategic Initiatives and Product Innovations - TipRanks
Femasys Revenue Jumps 85 Percent in Q2 - AOL.com
HC Wainwright & Co. Lowers FEMY Price Target to $8.00, Maintains Buy Rating - AInvest
H.C. Wainwright Reiterates Buy Rating for Femasys with $8 Price Target - AInvest
Femasys:HC Wainwright Maintains Buy, PT Down to $8 from $12 - AInvest
Femasys earnings matched, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Femasys earnings matched, revenue fell short of estimates - Investing.com India
Femasys Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Femasys Reports Q2 GAAP EPS of -$0.16, Sales Increase 84.8% to $409,268. - AInvest
Femasys reports Q2 EPS (16c) vs. (21c) last year - TipRanks
Options Data Show Bullish Bias in Femasys Inc.Portfolio Diversification Stock Ideas From Experts - beatles.ru
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates - MSN
Is Femasys Inc. a turnaround storyBig Picture ROI Planning - kangso.co.kr
Femasys Q2 2025 Financial Results: A Strategic Inflection Point for Women's Health Innovation - AInvest
Femasys 2025 Q2 Earnings Slight Earnings Improvement Amid Persistent Losses - AInvest
Femasys Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Femasys Announces Second Quarter Financial Results for 2025 - GlobeNewswire
Femasys Inc. (FEMY): Navigating Financial Challenges and Product Viability in a Competitive Women's Health Market - AInvest
Femasys Q2 Earnings Miss Estimates, Revenue Down 48.88% - AInvest
Femasys Q2 Revenue Surges 85%, Posts Narrower Net Loss and Gains European Approval for FemBloc. - AInvest
Femasys Revenue Jumps 85 Percent in Q2 - The Motley Fool
Femasys Inc reports results for the quarter ended June 30Earnings Summary - TradingView
FEMASYS INC SEC 10-Q Report - TradingView
Femasys Announces Q2 Financial Results, Regulatory Approvals, and Commercial Progress. - AInvest
Femasys secures first European order for FemBloc - MSN
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion - GlobeNewswire
Femasys Inc. shares fall 4.54% intraday despite securing first European order for FemBloc. - AInvest
Femasys secures first European order for FemBloc, marking strategic milestone in global expansion - MarketScreener
Femasys Inc. Secures First European Order for Fembloc, Marking Strategic Milestone in Global Expansion - MarketScreener
Femasys Enters European Market with Major Spain Order - TipRanks
Femasys' Breakthrough in Non-Surgical Contraception: A Disruptive Force in a Fragmented Market - AInvest
Femasys receives first European commercial order for FemBloc contraceptive By Investing.com - Investing.com Nigeria
Femasys Secures First European Order for FemBloc Permanent Birth Control Solution - AInvest
Femasys receives first European commercial order for FemBloc contraceptive - Investing.com
Femasys Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
What are Femasys Inc. company’s key revenue driversRapidly growing investment returns - Jammu Links News
What analysts say about Femasys Inc. stockInvest confidently with professional market insights - Jammu Links News
Is Femasys Inc. a good long term investmentGet alerts on top growth stocks daily - Jammu Links News
How many analysts rate Femasys Inc. as a “Buy”Get exclusive market analysis for investors - Jammu Links News
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):